Special Issue

Role of New Clinical, Biologic Factors and Prognostic Systems in the Clinical Management of Chronic Lymphocytic Leukemia

Message from the Guest Editor

  Chronic lymphocytic leukemia (CLL), the most common adult leukemia, is a clinically heterogeneous disease with an indolent course in some patients, while others show an aggressive disease and poor survival. More than 40 years ago, Rai and Binet developed a staging system that is still one of the mainstays to predict the outcome of CLL patients. Recent advances in the knowledge of the biology of CLL have led to identifying some prognostic biomarkers that can better predict the outcome of patients. The most reliable prognostic markers, widely used in clinical practice, are the immunoglobulin heavy chain variable (*IGHV*) gene mutational status, *TP53* mutations*,* and cytogenetic aberrations identified by fluorescence in situ hybridization (FISH;11q–, 13q–, +12 and 17p–). Some of these biomarkers, *TP53* aberrations, and the IGHV gene mutational status, can also drive treatment decisions. A multitude of other biomarkers, such as CD38, CD49d, and ZAP70 expression, *NOTCH1, SF3B1*, and *BIRC3* gene mutations, have also revealed a prognostic effect in CLL.

Guest Editor

Prof. Dr. Francesca Romana Mauro

Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, 00161 Rome, Italy

Deadline for manuscript submissions

closed (1 May 2021)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)